Bio-Techne Announces Dividend for Q3 2026

MINNEAPOLIS, Nov. 3, 2026 /CourierPR/ -- Bio-Techne Corporation, a global life sciences company, has announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. The quarterly dividend will be payable on November 23, 2026, to all common shareholders of record at the close of business on November 13, 2026, provided that the company's previously announced transaction with Merck KGaA, Darmstadt, Germany, does not close on or before the close of business on November 13, 2026.

Bio-Techne Corporation, which provides innovative tools and bioactive reagents for the research and clinical diagnostic communities, generated over $1.2 billion in net sales in fiscal 2026 and has approximately 3,000 employees worldwide. The company's products assist scientific investigations into biological processes and the nature and progress of specific diseases, aiding in drug discovery efforts and providing the means for accurate clinical tests and diagnoses. With a diverse portfolio of thousands of products, Bio-Techne continues to be a significant player in the global life sciences industry.

The dividend decision comes as the company faces the possibility of a significant transaction with Merck KGaA, Darmstadt, Germany. This pending acquisition, if completed, could impact the company's future dividend policies. Bio-Techne's forward-looking statements warn that the timing of the transaction's completion, including whether it closes on or before the dividend record date, is subject to various risks and uncertainties. The company also notes that the satisfaction of the conditions to the pending transaction, including receipt of required shareholder and regulatory approvals, is a critical factor in the transaction's success.

The release also includes a forward-looking statement section, which cautions investors not to place undue emphasis on the statements made. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The company undertakes no obligation to update or revise any forward-looking statements due to new information or future events. Investors are advised to carefully consider the factors described under "Risk Factors" in the company's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as filed with the U.S. Securities and Exchange Commission.